FDA's drug approvals database records a supplemental approval on 2 September 2026 for abrocitinib, the oral JAK1 inhibitor used for moderate to severe atopic dermatitis.
The record names the application but not what the supplement changes. Supplements can cover labelling, safety wording, manufacturing or dosing as well as new indications, so this entry alone does not show a change a prescriber needs to act on.
JAK inhibitors carry boxed warnings on serious infection, mortality, malignancy, major cardiovascular events and thrombosis, so any label update to this class is worth reading when the revised label is posted. CDSCO's position on the change is not known.
- Check the updated abrocitinib label on FDA's site before assuming anything has changed for prescribing.
- Keep screening for tuberculosis and hepatitis B before starting any JAK inhibitor.
- Review cardiovascular and thrombotic risk before prescribing a JAK inhibitor, especially in patients over 65 or who smoke.
- Do not treat a supplemental approval as a new indication until the label confirms it.
Why it matters
Label changes to JAK inhibitors often concern safety, and prescribers are the last check before a patient is exposed.
Don't overread it
A licence supplement is not necessarily a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free